Drug pricing review group raises recommended price for Gilead's remdesivir - Reuters

8:45am PDT - June 24th, 2020    remdesivir - Reuters

The Institute for Clinical and Economic Review on Wednesday boosted its benchmark price for Gilead Sciences Inc's remdesivir, suggesting the antiviral could be priced up to $5,080, based on benefits shown in COVID-19 patients.